Literature DB >> 21317885

UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53.

Hong Wu1, Scott L Pomeroy, Manuel Ferreira, Natalia Teider, Juliana Mariani, Keiichi I Nakayama, Shigetsugu Hatakeyama, Victor A Tron, Linda F Saltibus, Leo Spyracopoulos, Roger P Leng.   

Abstract

The TP53 gene (encoding the p53 tumor suppressor) is rarely mutated, although frequently inactivated, in medulloblastoma and ependymoma. Recent work in mouse models showed that the loss of p53 accelerated the development of medulloblastoma. The mechanism underlying p53 inactivation in human brain tumors is not completely understood. We show that ubiquitination factor E4B (UBE4B), an E3 and E4 ubiquitin ligase, physically interacts with p53 and Hdm2 (also known as Mdm2 in mice). UBE4B promotes p53 polyubiquitination and degradation and inhibits p53-dependent transactivation and apoptosis. Notably, silencing UBE4B expression impairs xenotransplanted tumor growth in a p53-dependent manner and overexpression of UBE4B correlates with decreased expression of p53 in these tumors. We also show that UBE4B overexpression is often associated with amplification of its gene in human brain tumors. Our data indicate that amplification and overexpression of UBE4B represent previously undescribed molecular mechanisms of inactivation of p53 in brain tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317885     DOI: 10.1038/nm.2283

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  42 in total

1.  A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly.

Authors:  M Koegl; T Hoppe; S Schlenker; H D Ulrich; T U Mayer; S Jentsch
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

Review 2.  Ubiquitin in chains.

Authors:  C M Pickart
Journal:  Trends Biochem Sci       Date:  2000-11       Impact factor: 13.807

Review 3.  How the cyclin became a cyclin: regulated proteolysis in the cell cycle.

Authors:  D M Koepp; J W Harper; S J Elledge
Journal:  Cell       Date:  1999-05-14       Impact factor: 41.582

4.  UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination.

Authors:  Mitsuchika Hosoda; Toshinori Ozaki; Kou Miyazaki; Syunji Hayashi; Kazushige Furuya; Ken-Ichi Watanabe; Takahito Nakagawa; Takayuki Hanamoto; Satoru Todo; Akira Nakagawara
Journal:  Oncogene       Date:  2005-11-03       Impact factor: 9.867

5.  U box proteins as a new family of ubiquitin-protein ligases.

Authors:  S Hatakeyama; M Yada; M Matsumoto; N Ishida; K I Nakayama
Journal:  J Biol Chem       Date:  2001-07-02       Impact factor: 5.157

6.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

7.  Cell-cycle arrest versus cell death in cancer therapy.

Authors:  T Waldman; Y Zhang; L Dillehay; J Yu; K Kinzler; B Vogelstein; J Williams
Journal:  Nat Med       Date:  1997-09       Impact factor: 53.440

8.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

9.  The ubiquitin ligase COP1 is a critical negative regulator of p53.

Authors:  David Dornan; Ingrid Wertz; Harumi Shimizu; David Arnott; Gretchen D Frantz; Patrick Dowd; Karen O'Rourke; Hartmut Koeppen; Vishva M Dixit
Journal:  Nature       Date:  2004-04-21       Impact factor: 49.962

Review 10.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  50 in total

1.  Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Authors:  Annette Künkele; Katleen De Preter; Lukas Heukamp; Theresa Thor; Kristian W Pajtler; Wolfgang Hartmann; Michel Mittelbronn; Michael A Grotzer; Hedwig E Deubzer; Frank Speleman; Alexander Schramm; Angelika Eggert; Johannes H Schulte
Journal:  Neuro Oncol       Date:  2012-05-16       Impact factor: 12.300

2.  The Roles of MDM2 and MDMX Phosphorylation in Stress Signaling to p53.

Authors:  Jiandong Chen
Journal:  Genes Cancer       Date:  2012-03

Review 3.  Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

Authors:  Lindsey N Micel; John J Tentler; Peter G Smith; Gail S Eckhardt
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

4.  Activity-enhancing mutations in an E3 ubiquitin ligase identified by high-throughput mutagenesis.

Authors:  Lea M Starita; Jonathan N Pruneda; Russell S Lo; Douglas M Fowler; Helen J Kim; Joseph B Hiatt; Jay Shendure; Peter S Brzovic; Stanley Fields; Rachel E Klevit
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

5.  It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53.

Authors:  Ian M Love; Steven R Grossman
Journal:  Genes Cancer       Date:  2012-03

6.  HDM2 promotes WIP1-mediated medulloblastoma growth.

Authors:  Meghan C Buss; Tracy-Ann Read; Matthew J Schniederjan; Khanjan Gandhi; Robert C Castellino
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

7.  UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.

Authors:  Peter E Zage; Natalie Sirisaengtaksin; Yin Liu; Monica Gireud; Brandon S Brown; Shana Palla; Kristen N Richards; Dennis P M Hughes; Andrew J Bean
Journal:  Cancer       Date:  2012-09-18       Impact factor: 6.860

8.  The E3 ligase PIRH2 polyubiquitylates CHK2 and regulates its turnover.

Authors:  M Bohgaki; A Hakem; M J Halaby; T Bohgaki; Q Li; P A Bissey; J Shloush; T Kislinger; O Sanchez; Y Sheng; R Hakem
Journal:  Cell Death Differ       Date:  2013-03-01       Impact factor: 15.828

9.  The Many Faces of MDM2 Binding Partners.

Authors:  Maurisa F Riley; Guillermina Lozano
Journal:  Genes Cancer       Date:  2012-03

10.  The transcription factor MEF/Elf4 is dually modulated by p53-MDM2 axis and MEF-MDM2 autoregulatory mechanism.

Authors:  Mary Ann Suico; Ryosuke Fukuda; Rui Miyakita; Kosuke Koyama; Manabu Taura; Tsuyoshi Shuto; Hirofumi Kai
Journal:  J Biol Chem       Date:  2014-07-31       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.